| Author            | Year | Design     | N cirrhotic patients with VTE | Cause of liver disease                          | Male (%) | Age | Child-Pugh | MELD | Ascitis (%) | Variceal bleeding (%) | HCC (%) | Malignancy (%) | Previous VTE (%) | Acute infection (%) | Albumine (g/dL) | Platelets (10⁹/mm⁴) | INR |
|------------------|------|------------|------------------------------|------------------------------------------------|----------|-----|------------|------|-------------|----------------------|---------|----------------|------------------|-------------------|----------------|------------------|-----|
| Aldawood et al.  | 2011 | Case-control | 6                           | Hep C, Hep B, cryptogenic                         | 33       | 64  | 10.3       | NI   | NI          | 33                   | 17      | NI            | NI                | 33                | 2.6            | 201              | 1.55|
| Ali et al.       | 2011 | Case-control | 8248                        | NI                                              | 59       | 58  | NI         | NI   | 26          | 6                   | NI      | NI            | NI                | NI                | NI             | NI               | NI  |
| Barba et al.     | 2018 | Cohort      | 318453                       | NI                                              | 31       | 65  | NI         | NI   | NI          | 2                   | NI      | 12            | NI                | NI                | NI             | NI               | NI  |
| Bogari et al.    | 2014 | Cohort      | 18                           | NI                                              | 67       | 54  | 17.8       | NI   | NI          | 22                   | 0       | 12            | 2.6               | 184               | 1.4            |                  |     |
| Girleanu et al.  | 2012 | Case-control | 78                           | NI                                              | 63       | 60  | 7.7        | 13.2 | 58          | NI                   | NI      | NI            | 22                | 2.5                | 101            | 1.6              |     |
| Lesmana et al.   | 2010 | Case-control | 78                           | Hep C, Hep B                                    | 12       | NI   | NI         | 50   | NI          | 33                   | NI      | NI            | NI                | 2.8               | 131            | NI               |     |
| Lizardaga et al. | 2010 | Matched Case-control | 108 | Viral, alcohol, autoimmune, NASH, hemochromatosis, cryptogenic | 64       | 56  | NI         | NI   | NI          | NI                   | NI      | NI            | NI                | 2.3               | 143            | NI               |     |
| Sagarda et al.   | 2009 | Matched Case-control | 99464 | NASH, alcohol                         | 47       | NI   | NI         | NI   | NI          | 17                   | NI      | NI            | NI                | NI                | NI             | NI               |     |
| Stine et al.     | 2018 | Matched Case-control | 145 | NASH, cryptogenic, Hep C, alcohol, autoimmune, cholestatic, Hep B, hemochromatosis | 62       | 59  | NI         | 15.7 | 69          | 53                   | 11      | 12            | 22                | 47                | 2.9            | 153              | 1.5 |
| Walsh et al.     | 2013 | Matched Case-control | 27                           | NI                                              | NI       | NI   | 17         | NI   | NI          | NI                   | NI      | NI            | NI                | 2.1               | 103            | 1.5              |     |
| Zhang et al.     | 2016 | Case-control | 9                            | Hep B, alcohol                                   | 89       | 57  | 12.4       | 88   | NI          | NI                   | NI      | NI            | NI                | 2.9               | 75             | 1.7              |     |

| Author            | Year | Design     | N cirrhotic patients without VTE | Cause of liver disease                          | Male (%) | Age | Child-Pugh | MELD | Ascitis (%) | Variceal bleeding (%) | HCC (%) | Malignancy (%) | Previous VTE (%) | Acute infection (%) | Albumine (g/dL) | Platelets (10⁹/mm⁴) | INR |
|------------------|------|------------|------------------------------|------------------------------------------------|----------|-----|------------|------|-------------|----------------------|---------|----------------|------------------|-------------------|----------------|------------------|-----|
| Aldawood et al.  | 2011 | Case-control | 220                         | Hep C, Hep B, cryptogenic, autoimmune             | 63       | 63  | 8.25       | NI   | NI          | 24                   | NI      | 45            | NI                | 54                | 3              | 136              | 1.3 |
| Ali et al.       | 2011 | Case-control | 441551                       | NI                                              | 61       | 58  | NI         | NI   | 31          | 9                   | NI      | NI            | NI                | NI                | NI             | NI               | NI  |
| Barba et al.     | 2018 | Cohort      | 318453                       | NI                                              | 34       | 65  | NI         | NI   | 3           | <1                  | 13      | NI            | NI                | NI                | NI             | NI               | NI  |
| Bogari et al.    | 2014 | Cohort      | 145                          | NI                                              | 65       | 54  | 16.8       | NI   | NI          | 19                   | NI      | 1             | 57                | 2.6               | 124            | 1.5              |     |
| Girleanu et al.  | 2012 | Case-control | 160                         | NI                                              | 63       | 55  | 7.9        | 10.3 | 49          | NI                   | NI      | NI            | 7                 | 3.2               | 109            | 1.5              |     |
| Lesmana et al.   | 2010 | Case-control | 244                         | Hep B, Hep C, Alcohol, NASH                      | 64       | NI   | NI         | NI   | 50          | 34                   | NI      | NI            | 3                 | 148               | NI             |                  |     |
| Lizardaga et al. | 2010 | Matched Case-control | 108 | Cryptogenic, viral, alcohol, NASH, autoimmune, hemochromatosis | 64       | 56  | NI         | NI   | NI          | NI                   | NI      | NI            | NI                | 2.4               | 109            | NI               |     |
| Authors       | Year   | Design       | Study Population                          | Cases | Controls | Matching Variables                          | OR    | 95% CI Low | 95% CI High | OR    | 95% CI Low | 95% CI High | OR    | 95% CI Low | 95% CI High |
|--------------|--------|--------------|-------------------------------------------|-------|----------|--------------------------------------------|-------|------------|------------|-------|------------|------------|-------|------------|------------|
| Søgaard et al. | 2009   | Matched Case-control | NASH, alcohol                             | 47    | 496979   |                                             | NI    | NI         | NI         | NI    | NI         | NI         | NI    | NI         | NI         |
| Stine et al.  | 2018   | Matched Case-control | NASH, cryptogenic, Hep C, alcohol, cholestatic, hemochromatosis, autoimmune | 62    | 58       | NI                                          | 16.3  | 69         | 51         | 14    | 12         | 3.5        | 31    | 2.9        | 115        |
| Walsh et al.  | 2013   | Matched Case-control | NI                                         | NI    | 81       | NI                                          | NI    | NI         | NI         | 17    | NI         | NI         | NI    | NI         | NI         |
| Zhang et al.  | 2016   | Case-control | Alcohol, Hep B, Hep C, autoimmune, cholestatic, drug | 66    | 56       | NI                                          | 7.4   | 49         | NI         | 17    | NI         | NI         | 2.4   | 3.5        | 31         |

**Supplementary Table 2.** Baseline characteristics of the included studies. Studies comparing cirrhotic with VTE vs. cirrhotic without VTE. NI: Not informed; NA: Not applicable; HCC: Hepatocellular carcinoma; VTE: Venous thromboembolism